Neutrophils pro-inflammatory and anti-inflammatory cytokine release in patients with heart failure and reduced ejection fraction

Aims Heart failure with reduced ejection fraction (HFrEF) is characterized by sub-clinical inflammation. Changes in selected biomarkers of inflammation concomitant with the release of pro-inflammatory and anti-inflammatory cytokines by neutrophils have not been investigated in patients with HFrEF. Methods and results Fifty-two patients, aged 68.8 +/- 1.7 years, with HFrEF and left ventricular ejection fraction 28.7 +/- 1.0%, and 21 healthy controls (CTL) were recruited. Twenty-five HF patients had type 2 diabetes. Venous blood samples from HF and CTL were collected once. Neutrophil-derived pro-inflammatory and anti-inflammatory cytokine levels were assessed in plasma by ELISA. Plasma biomarkers assessed included: C-reactive protein (CRP), vascular endothelial growth factor (VEGF), interleukins (IL)-6, -8, -1 receptor antagonist (-1RA), nitric oxide (NO), soluble intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule 1 (sVCAM-1) and E-Selectin (sE-Sel). Neutrophils were isolated and stimulated with various agonists to promote VEGF, IL-6, IL-8, and IL-1RA release. Compared with CTL, HFrEF patients showed a marked decrease in circulating VEGF [178.0 (interquartile range; IQR 99.6; 239.2) vs. 16.2 (IQR 9.3; 20.2) pg/mL, P <= 0.001] and NO [45.2 (IQR 42.1; 57.6) vs. 40.6 (IQR 30.4; 47.1) pg/mL, P = 0.0234]. All other circulating biomarkers were significantly elevated. Neutrophils isolated from patients with HFrEF exhibited a greater IL-8 release in response to LPS [1.2 +/- 0.1 (CTL); 10.4 +/- 1.6 ng/mL (HFrEF) and 12.4 +/- 1.6 ng/mL (HFrEF and DM), P <= 0.001]. IL-6 release in response to LPS was not changed in HFrEF patients without diabetes, whereas it was significantly increased in patients with HFrEF and diabetes [46.7 +/- 3.9 (CTL) vs. 165.8 +/- 48.0 pg/mL (HFrEF), P = 0.1713 and vs. 397.7 +/- 67.4 pg/mL (HFrEF and DM), P <= 0.001]. In contrast, the release of VEGF and IL-1RA was significantly reduced in HFrEF (VEGF; TNF-alpha: 38.6 +/- 3.1 and LPS: 25.3 +/- 2.6 pg/mL; IL1RA; TNF-alpha: 0.6 +/- 0.04 and LPS: 0.3 +/- 0.02 ng/mL) compared with CTL (VEGF; TNF-alpha: 60.0 +/- 9.4 and LPS: 41.2 +/- 5.9 pg/mL; IL1RA; TNF-alpha: 3.3 +/- 0.2 and LPS: 2.3 +/- 0.1 ng/mL). Conclusions Patients with HFrEF exhibit a significant decrease in circulating VEGF. The release of VEGF and both pro-inflammatory and anti-inflammatory cytokines from the stimulated neutrophils is markedly altered in these patients. The clinical significance of these findings deserves further investigation.